Goldman Sachs Comments On Management Meetings With Vertex Pharmaceuticals

According to Goldman Sachs, Vertex Pharmaceuticals VRTX held recent management meetings. Goldman Sachs reported that it recently hosted meetings with Vertex Pharmaceuticals CFO Ian Smith. “Discussions focused on three areas: (1) TVR FDA advisory committee panel and launch trajectory for hepatitis C, (2) expectations for the EASL hepC conference and (3) the potential market opportunity for VX-770 for cystic fibrosis (CF). We maintain our 12-month price target of $52 which is derived from a 42.5%/42.5%/15% blend of our SOTP ($45)/DCF ($50)/M&A value ($76).” Vertex Pharmaceuticals closed yesterday at $46.91.